nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.06.2008 | Review

Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer

verfasst von: Laura C. Kelley, Sohrab Shahab, Scott A. Weed

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Coordinated regulation of the actin cytoskeleton is central to cell motility, invasion and metastasis. Head and neck squamous cell carcinoma (HNSCC) is a highly invasive disease displaying frequent lymph node metastasis, compounding patient management. HNSCC progression is characterized by frequent amplification of chromosome segments 3q26-29, 8q23-24 and 11q13, events that are associated with poor patient outcome. The relative frequency of these amplification events and correlation with invasive disease raises the potential that these regions harbor actin regulatory genes important in facilitating reorganization of the actin cytoskeleton to promote tumor invasion. Identification of the actin cytoskeletal regulatory genes located within the 3q26-29, 8q23-24 and 11q13 amplicons will provide an important first step towards the comprehensive understanding of the molecular events that govern invasion and metastasis in HNSCC and other tumors containing these amplifications. We utilized Ensembl MartView to conduct a gene mining analysis within chromosome segments 3q26-29, 8q23-24 and 11q13 to identify known and predicted regulators of actin-based cell movement, tumor invasion and metastasis. All examined chromosomal regions contain genes known that regulate the actin cytoskeleton, with several (PI3-kinase alpha, focal adhesion kinase (FAK) and cortactin) known to promote invasion in HNSCC and other carcinomas. Additional genes known to regulate motility and invasion were also identified. Amplification of chromosome 3q26-29, 8q23-24 and 11q13 therefore results in known or predicted overexpression of several key mediators that can act alone or potentially act in concert to promote actin-based cell invasion in HNSCC and other cancer types.

Kramer RH, Shen X, Zhou H (2005) Tumor cell invasion and survival in head and neck cancer. Cancer Metastasis Rev 24(1):35–45PubMedCrossRef

Howell GM, Grandis JR (2005) Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck 27(8):710–717PubMedCrossRef

Braakhuis BJ, Senft A, de Bree R et al (2006) Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma. J Clin Pathol 59(12):1254–1260PubMedCrossRef

Ginos MA, Page GP, Michalowicz BS et al (2004) Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64(1):55–63PubMedCrossRef

Chung CH, Parker JS, Karaca G et al (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5(5):489–500PubMedCrossRef

Yamazaki D, Kurisu S, Takenawa T (2005) Regulation of cancer cell motility through actin reorganization. Cancer Sci 96(7):379–386PubMedCrossRef

Yamaguchi H, Condeelis J (2006) Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 1773(5):642–652PubMed

Ridley AJ, Schwartz MA, Burridge K et al (2003) Cell migration: integrating signals from front to back. Science 302(5651):1704–1709PubMedCrossRef

Yamaguchi H, Wyckoff J, Condeelis J (2005) Cell migration in tumors. Curr Opin Cell Biol 17(5):559–564PubMedCrossRef

10.

Wells A (2000) Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 78:31–101PubMedCrossRef

11.

Avizienyte E, Frame MC (2005) Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 17(5):542–547PubMedCrossRef

12.

Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5(10):816–826PubMedCrossRef

13.

Frame MC, Brunton VG (2002) Advances in Rho-dependent actin regulation and oncogenic transformation. Curr Opin Genet Dev 12(1):36–43PubMedCrossRef

14.

Pollard TD, Borisy GG (2003) Cellular motility driven by assembly and disassembly of actin filaments. Cell 112(4):453–465PubMedCrossRef

15.

Friedl P, Brocker EB (2000) The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci 57(1):41–64PubMedCrossRef

16.

Sahai E (2005) Mechanisms of cancer cell invasion. Curr Opin Genet Dev 15(1):87–96PubMedCrossRef

17.

Condeelis J, Singer RH, Segall JE (2005) The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol 21:695–718PubMedCrossRef

18.

Gollin SM (2001) Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck 23(3):238–253PubMedCrossRef

19.

Bockmuhl U, Schluns K, Schmidt S, Matthias S, Petersen I (2002) Chromosomal alterations during metastasis formation of head and neck squamous cell carcinoma. Genes Chromosomes Cancer 33(1):29–35PubMedCrossRef

20.

Patmore HS, Cawkwell L, Stafford ND, Greenman J (2005) Unraveling the chromosomal aberrations of head and neck squamous cell carcinoma: a review. Ann Surg Oncol 12(10):831–842PubMedCrossRef

21.

Lin M, Smith LT, Smiraglia DJ et al (2006) DNA copy number gains in head and neck squamous cell carcinoma. Oncogene 25(9):1424–1433PubMedCrossRef

22.

Ashburner M, Ball CA, Blake JA et al (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium Nat Genet 25(1):25–29PubMedCrossRef

23.

Singh B, Gogineni SK, Sacks PG et al (2001) Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res 61(11):4506–4513PubMed

24.

Singh B, Stoffel A, Gogineni S et al (2002) Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am J Pathol 161(2):365–371PubMed

25.

Slebos RJ, Yi Y, Ely K et al (2006) Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12(3 Pt 1):701–709PubMedCrossRef

26.

Blobe GC, Stribling S, Obeid LM, Hannun YA (1996) Protein kinase C isoenzymes: regulation and function. Cancer Surv 27:213–248PubMed

27.

Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332( Pt 2):281–292PubMed

28.

Xu L, Deng X (2006) Protein kinase Ciota promotes nicotine-induced migration and invasion of cancer cells via phosphorylation of micro- and m-calpains. J Biol Chem 281(7):4457–4466PubMedCrossRef

29.

Regala RP, Weems C, Jamieson L et al (2005) Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65(19):8905–8911PubMedCrossRef

30.

Zhang L, Huang J, Yang N et al (2006) Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 66(9):4627–4635PubMedCrossRef

31.

Weichert W, Gekeler V, Denkert C, Dietel M, Hauptmann S (2003) Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int J Oncol 23(3):633–639PubMed

32.

Steed PM, Chow AH (2001) Intracellular signaling by phospholipase D as a therapeutic target. Curr Pharm Biotechnol 2(3):241–256PubMedCrossRef

33.

Jenkins GM, Frohman MA (2005) Phospholipase D: a lipid centric review. Cell Mol Life Sci 62(19–20):2305–2316PubMedCrossRef

34.

Kim JH, Kim HW, Jeon H, Suh PG, Ryu SH (2006) Phospholipase D1 regulates cell migration in a lipase activity-independent manner. J Biol Chem 281(23):15747–15756PubMedCrossRef

35.

Ahn BH, Kim SY, Kim EH et al (2003) Transmodulation between phospholipase D and c-Src enhances cell proliferation. Mol Cell Biol 23(9):3103–3115PubMedCrossRef

36.

Noh DY, Ahn SJ, Lee RA et al (2000) Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett 161(2):207–214PubMedCrossRef

37.

Zheng Y, Rodrik V, Toschi A et al (2006) Phospholipase D couples survival and migration signals in stress response of human cancer cells. J Biol Chem 281(23):15862–15868PubMedCrossRef

38.

Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30(2):193–204PubMedCrossRef

39.

Cantrell DA (2001) Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114(Pt 8):1439–1445PubMed

40.

Volinia S, Hiles I, Ormondroyd E et al (1994) Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. Genomics 24(3):472–477PubMedCrossRef

41.

Estilo CL, O-Charoenrat P, Ngai I et al (2003) The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. Clin Cancer Res 9(6):2300–2306

42.

Roymans D, Slegers H (2001) Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 268(3):487–498PubMedCrossRef

43.

Hill K, Welti S, Yu J et al (2000) Specific requirement for the p85-p110alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells. J Biol Chem 275(6):3741–3744PubMedCrossRef

44.

Tan M, Grijalva R, Yu D (1999) Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res 59(7):1620–1625PubMed

45.

Woenckhaus J, Steger K, Werner E et al (2002) Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 198(3):335–342PubMedCrossRef

46.

Tsukita S, Furuse M (2000) Pores in the wall: claudins constitute tight junction strands containing aqueous pores. J Cell Biol 149(1):13–16PubMedCrossRef

47.

Hewitt KJ, Agarwal R, Morin PJ (2006) The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6:186PubMedCrossRef

48.

Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18(4):511–518PubMedCrossRef

49.

Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65(21):9603–9606PubMedCrossRef

50.

Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T (2006) Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 66(10):5251–5257PubMedCrossRef

51.

Thelemann A, Petti F, Griffin G et al (2005) Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 4(4):356–376PubMedCrossRef

52.

van der Horst EH, Degenhardt YY, Strelow A et al (2005) Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci U S A 102(44):15901–15906PubMedCrossRef

53.

Manser E, Leung T, Salihuddin H, Tan L, Lim L (1993) A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 363(6427):364–367PubMedCrossRef

54.

Kato J, Kaziro Y, Satoh T (2000) Activation of the guanine nucleotide exchange factor Dbl following ACK1-dependent tyrosine phosphorylation. Biochem Biophys Res Commun 268(1):141–147PubMedCrossRef

55.

Eisenmann KM, McCarthy JB, Simpson MA et al (1999) Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1(8):507–513PubMedCrossRef

56.

Chodniewicz D, Klemke RL (2004) Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold. Biochim Biophys Acta 1692(2–3):63–76PubMed

57.

Yokoyama N, Lougheed J, Miller WT (2005) Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual hydroxyamino acid specificity in a tyrosine kinase. J Biol Chem 280(51):42219–42226PubMedCrossRef

58.

Galisteo ML, Yang Y, Urena J, Schlessinger J (2006) Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci U S A 103(26):9796–9801PubMedCrossRef

59.

Satoh T, Kato J, Nishida K, Kaziro Y (1996) Tyrosine phosphorylation of ACK in response to temperature shift-down, hyperosmotic shock, and epidermal growth factor stimulation. FEBS Lett 386(2–3):230–234PubMedCrossRef

60.

Mahajan NP, Whang YE, Mohler JL, Earp HS (2005) Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res 65(22):10514–10523PubMedCrossRef

61.

Huang Q, Yu GP, McCormick SA et al (2002) Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression. Genes Chromosomes Cancer 34(2):224–233PubMedCrossRef

62.

Bockmuhl U, Schwendel A, Dietel M, Petersen I (1996) Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Res 56(23):5325–5329PubMed

63.

Squire JA, Bayani J, Luk C et al (2002) Molecular cytogenetic analysis of head and neck squamous cell carcinoma: by comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head Neck 24(9):874–887PubMedCrossRef

64.

Stracke ML, Clair T, Liotta LA (1997) Autotaxin, tumor motility-stimulating exophosphodiesterase. Adv Enzyme Regul 37:135–144PubMedCrossRef

65.

Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML (2000) Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 19(2):241–247PubMedCrossRef

66.

Clair T, Lee HY, Liotta LA, Stracke ML (1997) Autotaxin is an exoenzyme possessing 5’-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities. J Biol Chem 272(2):996–1001PubMedCrossRef

67.

Lee HY, Clair T, Mulvaney PT et al (1996) Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J Biol Chem 271(40):24408–24412PubMedCrossRef

68.

Umezu-Goto M, Kishi Y, Taira A et al (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158(2):227–233PubMedCrossRef

69.

Hama K, Aoki J, Fukaya M et al (2004) Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 279(17):17634–17639PubMedCrossRef

70.

Nam SW, Clair T, Kim YS et al (2001) Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 61(18):6938–6944PubMed

71.

Yang Y, Mou L, Liu N, Tsao MS (1999) Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 21(2):216–222PubMed

72.

Yang SY, Lee J, Park CG et al (2002) Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 19(7):603–608PubMedCrossRef

73.

Lee YG, Macoska JA, Korenchuk S, Pienta KJ (2002) MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 4(4):291–294PubMedCrossRef

74.

Machesky LM, Johnston SA (2007) MIM: a multifunctional scaffold protein. J Mol Med 85(6):569–576PubMedCrossRef

75.

Bompard G, Sharp SJ, Freiss G, Machesky LM (2005) Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B. J Cell Sci 118(Pt 22):5393–5403PubMedCrossRef

76.

Lin J, Liu J, Wang Y et al (2005) Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein. Oncogene 24(12):2059–2066PubMedCrossRef

77.

Wang Y, Zhou K, Zeng X, Lin J, Zhan X (2007) Tyrosine phosphorylation of missing in metastasis protein is implicated in platelet-derived growth factor-mediated cell shape changes. J Biol Chem 282(10):7624–7631PubMedCrossRef

78.

Loberg RD, Neeley CK, Adam-Day LL et al (2005) Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology. Int J Oncol 26(6):1699–1705PubMed

79.

Nixdorf S, Grimm MO, Loberg R et al (2004) Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Lett 215(2):209–220PubMedCrossRef

80.

Utikal J, Gratchev A, Muller-Molinet I et al (2006) The expression of metastasis suppressor MIM/MTSS1 is regulated by DNA methylation. Int J Cancer 119(10):2287–2293PubMedCrossRef

81.

Schlaepfer DD, Mitra SK (2004) Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 14(1):92–101PubMedCrossRef

82.

McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5(7):505–515PubMedCrossRef

83.

Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT (1992) pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A 89(11):5192–5196PubMedCrossRef

84.

Kanner SB, Reynolds AB, Vines RR, Parsons JT (1990) Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci U S A 87(9):3328–3332PubMedCrossRef

85.

Ilic D, Furuta Y, Kanazawa S et al (1995) Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377(6549):539–544PubMedCrossRef

86.

Hsia DA, Mitra SK, Hauck CR et al (2003) Differential regulation of cell motility and invasion by FAK. J Cell Biol 160(5):753–767PubMedCrossRef

87.

Gabarra-Niecko V, Schaller MD, Dunty JM (2003) FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 22(4):359–374PubMedCrossRef

88.

Canel M, Secades P, Rodrigo JP et al (2006) Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res 12(11 Pt 1):3272–3279PubMedCrossRef

89.

Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11(19 Pt 1):6924–6932PubMedCrossRef

90.

van Nimwegen MJ, van de Water B (2007) Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 73(5):597–609PubMedCrossRef

91.

Shi Q, Hjelmeland AB, Keir ST et al (2007) A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 46(6):488–496PubMedCrossRef

92.

Slack-Davis JK, Martin KH, Tilghman RW et al (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282(20):14845–14852PubMedCrossRef

93.

Randazzo PA, Andrade J, Miura K et al (2000) The Arf GTPase-activating protein ASAP1 regulates the actin cytoskeleton. Proc Natl Acad Sci U S A 97(8):4011–4016PubMedCrossRef

94.

Sabe H, Onodera Y, Mazaki Y, Hashimoto S (2006) ArfGAP family proteins in cell adhesion, migration and tumor invasion. Curr Opin Cell Biol 18(5):558–564PubMedCrossRef

95.

Randazzo PA, Hirsch DS (2004) Arf GAPs: multifunctional proteins that regulate membrane traffic and actin remodelling. Cell Signal 16(4):401–413PubMedCrossRef

96.

Kam JL, Miura K, Jackson TR et al (2000) Phosphoinositide-dependent activation of the ADP-ribosylation factor GTPase-activating protein ASAP1. Evidence for the pleckstrin homology domain functioning as an allosteric site. J Biol Chem 275(13):9653–9663PubMedCrossRef

97.

Brown MT, Andrade J, Radhakrishna H, Donaldson JG, Cooper JA, Randazzo PA (1998) ASAP1, a phospholipid-dependent arf GTPase-activating protein that associates with and is phosphorylated by Src. Mol Cell Biol 18(12):7038–7051PubMed

98.

D’Souza-Schorey C, Chavrier P (2006) ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol 7(5):347–358PubMedCrossRef

99.

Liu Y, Loijens JC, Martin KH, Karginov AV, Parsons JT (2002) The association of ASAP1, an ADP ribosylation factor-GTPase activating protein, with focal adhesion kinase contributes to the process of focal adhesion assembly. Mol Biol Cell 13(6):2147–2156PubMedCrossRef

100.

Onodera Y, Hashimoto S, Hashimoto A et al (2005) Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. Embo J 24(5):963–973PubMedCrossRef

101.

Hashimoto S, Hirose M, Hashimoto A et al (2006) Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. Proc Natl Acad Sci U S A 103(18):7036–7041PubMedCrossRef

102.

Ehlers JP, Worley L, Onken MD, Harbour JW (2005) DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer Res 11(10):3609–3613PubMedCrossRef

103.

Huang X, Godfrey TE, Gooding WE, McCarty KS Jr, Gollin SM (2006) Comprehensive genome and transcriptome analysis of the 11q13 amplicon in human oral cancer and synteny to the 7F5 amplicon in murine oral carcinoma. Genes Chromosomes Cancer 45(11):1058–1069PubMedCrossRef

104.

Bockmuhl U, Schluns K, Kuchler I, Petersen S, Petersen I (2000) Genetic imbalances with impact on survival in head and neck cancer patients. Am J Pathol 157(2):369–375PubMed

105.

Joberty G, Perlungher RR, Macara IG (1999) The Borgs, a new family of Cdc42 and TC10 GTPase-interacting proteins. Mol Cell Biol 19(10):6585–6597PubMed

106.

Hirsch DS, Pirone DM, Burbelo PD (2001) A new family of Cdc42 effector proteins, CEPs, function in fibroblast and epithelial cell shape changes. J Biol Chem 276(2):875–883PubMedCrossRef

107.

Joberty G, Perlungher RR, Sheffield PJ et al (2001) Borg proteins control septin organization and are negatively regulated by Cdc42. Nat Cell Biol 3(10):861–866PubMedCrossRef

108.

Finger FP (2002) One ring to bind them. Septins and actin assembly. Dev Cell 3(6):761–763PubMedCrossRef

109.

Belbin TJ, Singh B, Smith RV et al (2005) Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg 131(1):10–18PubMedCrossRef

110.

Glading A, Lauffenburger DA, Wells A (2002) Cutting to the chase: calpain proteases in cell motility. Trends Cell Biol 12(1):46–54PubMedCrossRef

111.

Franco SJ, Huttenlocher A (2005) Regulating cell migration: calpains make the cut. J Cell Sci 118(Pt 17):3829–3838PubMedCrossRef

112.

Franco S, Perrin B, Huttenlocher A (2004) Isoform specific function of calpain 2 in regulating membrane protrusion. Exp Cell Res 299(1):179–187PubMedCrossRef

113.

Franco SJ, Rodgers MA, Perrin BJ et al (2004) Calpain-mediated proteolysis of talin regulates adhesion dynamics. Nat Cell Biol 6(10):977–983PubMedCrossRef

114.

Kulkarni S, Saido TC, Suzuki K, Fox JE (1999) Calpain mediates integrin-induced signaling at a point upstream of Rho family members. J Biol Chem 274(30):21265–21275PubMedCrossRef

115.

Bialkowska K, Kulkarni S, Du X, Goll DE, Saido TC, Fox JE (2000) Evidence that beta3 integrin-induced Rac activation involves the calpain-dependent formation of integrin clusters that are distinct from the focal complexes and focal adhesions that form as Rac and RhoA become active. J Cell Biol 151(3):685–696PubMedCrossRef

116.

Wu M, Yu Z, Fan J, Caron A, Whiteway M, Shen SH (2006) Functional dissection of human protease mu-calpain in cell migration using RNAi. FEBS Lett 580(13):3246–3256PubMedCrossRef

117.

Sawhney RS, Cookson MM, Omar Y, Hauser J, Brattain MG (2006) Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway. J Biol Chem 281(13):8497–8510PubMedCrossRef

118.

Reichrath J, Welter C, Mitschele T et al (2003) Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. J Pathol 199(4):509–516PubMedCrossRef

119.

Turhani D, Krapfenbauer K, Thurnher D, Langen H, Fountoulakis M (2006) Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 27(7):1417–1423PubMedCrossRef

120.

Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS (2004) Cofilin promotes actin polymerization and defines the direction of cell motility. Science 304(5671):743–746PubMedCrossRef

121.

Yamaguchi H, Lorenz M, Kempiak S et al (2005) Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol 168(3):441–452PubMedCrossRef

122.

Huang TY, DerMardirossian C, Bokoch GM (2006) Cofilin phosphatases and regulation of actin dynamics. Curr Opin Cell Biol 18(1):26–31PubMedCrossRef

123.

Song X, Chen X, Yamaguchi H, Mouneimne G, Condeelis JS, Eddy RJ (2006) Initiation of cofilin activity in response to EGF is uncoupled from cofilin phosphorylation and dephosphorylation in carcinoma cells. J Cell Sci 119(Pt 14):2871–2881PubMedCrossRef

124.

Mouneimne G, Soon L, DesMarais V et al (2004) Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation. J Cell Biol 166(5):697–708PubMedCrossRef

125.

Mangone FR, Brentani MM, Nonogaki S et al (2005) Overexpression of Fos-related antigen-1 in head and neck squamous cell carcinoma. Int J Exp Pathol 86(4):205–212PubMedCrossRef

126.

Young MR, Colburn NH (2006) Fra-1 a target for cancer prevention or intervention. Gene 379:1–11PubMedCrossRef

127.

van Dam H, Castellazzi M (2001) Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis. Oncogene 20(19):2453–2464PubMedCrossRef

128.

Bergers G, Graninger P, Braselmann S, Wrighton C, Busslinger M (1995) Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol Cell Biol 15(7):3748–3758PubMed

129.

Belguise K, Kersual N, Galtier F, Chalbos D (2005) FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24(8):1434–1444PubMedCrossRef

130.

Ramos-Nino ME, Scapoli L, Martinelli M, Land S, Mossman BT (2003) Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res 63(13):3539–3545PubMed

131.

Young MR, Nair R, Bucheimer N et al (2002) Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. Mol Cell Biol 22(2):587–598PubMedCrossRef

132.

Casalino L, De Cesare D, Verde P (2003) Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol 23(12):4401–4415PubMedCrossRef

133.

Vial E, Sahai E, Marshall CJ (2003) ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4(1):67–79PubMedCrossRef

134.

Kjoller L, Hall A (2001) Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 152(6):1145–1157PubMedCrossRef

135.

Shuster MI, Han L, Le Beau MM et al (2000) A consistent pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a breakage-fusion-bridge cycle model for 11q13 amplification. Genes Chromosomes Cancer 28(2):153–163PubMedCrossRef

136.

Bliss JM, Venkatesh B, Colicelli J (2005) The RIN Family of Ras Effectors. Methods Enzymol 407:335–344

137.

Hu H, Bliss JM, Wang Y, Colicelli J (2005) RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Curr Biol 15(9):815–823PubMedCrossRef

138.

Takino T, Tamura M, Miyamori H et al (2003) Tyrosine phosphorylation of the CrkII adaptor protein modulates cell migration. J Cell Sci 116(Pt 15):3145–3155PubMedCrossRef

139.

Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA (1998) CAS/Crk coupling serves as a “molecular switch” for induction of cell migration. J Cell Biol 140(4):961–972PubMedCrossRef

140.

Boyle SN, Michaud GA, Schweitzer B, Predki PF, Koleske AJ (2007) A critical role for cortactin phosphorylation by Abl-family kinases in PDGF-induced dorsal-wave formation. Curr Biol 17(5):445–451PubMedCrossRef

141.

Niwa R, Nagata-Ohashi K, Takeichi M, Mizuno K, Uemura T (2002) Control of actin reorganization by Slingshot, a family of phosphatases that dephosphorylate ADF/cofilin. Cell 108(2):233–246PubMedCrossRef

142.

Ohta Y, Kousaka K, Nagata-Ohashi K et al (2003) Differential activities, subcellular distribution and tissue expression patterns of three members of Slingshot family phosphatases that dephosphorylate cofilin. Genes Cells 8(10):811–824PubMedCrossRef

143.

Uetrecht AC, Bear JE (2006) Coronins: the return of the crown. Trends Cell Biol 16(8):421–426PubMedCrossRef

144.

de Hostos EL, Bradtke B, Lottspeich F, Guggenheim R, Gerisch G (1991) Coronin, an actin binding protein of Dictyostelium discoideum localized to cell surface projections, has sequence similarities to G protein beta subunits. Embo J 10(13):4097–4104PubMed

145.

Gatfield J, Albrecht I, Zanolari B, Steinmetz MO, Pieters J (2005) Association of the leukocyte plasma membrane with the actin cytoskeleton through coiled coil-mediated trimeric coronin 1 molecules. Mol Biol Cell 16(6):2786–2798PubMedCrossRef

146.

Humphries CL, Balcer HI, D’Agostino JL et al (2002) Direct regulation of Arp2/3 complex activity and function by the actin binding protein coronin. J Cell Biol 159(6):993–1004PubMedCrossRef

147.

Cai L, Holoweckyj N, Schaller MD, Bear JE (2005) Phosphorylation of coronin 1B by protein kinase C regulates interaction with Arp2/3 and cell motility. J Biol Chem 280(36):31913–31923PubMedCrossRef

148.

Cai L, Marshall TW, Uetrecht AC, Schafer DA, Bear JE (2007) Coronin 1B coordinates Arp2/3 complex and cofilin activities at the leading edge. Cell 128(5):915–929PubMedCrossRef

149.

Schuuring E (1995) The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes–a review. Gene 159(1):83–96PubMedCrossRef

150.

Rodrigo JP, Garcia LA, Ramos S, Lazo PS, Suarez C (2000) EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 6(8):3177–3182PubMed

151.

Rothschild BL, Shim AH, Ammer AG et al (2006) Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 66(16):8017–8025PubMedCrossRef

152.

Cosen-Binker LI, Kapus A (2006) Cortactin: the gray eminence of the cytoskeleton. Physiology (Bethesda) 21:352–361

153.

Weaver AM, Karginov AV, Kinley AW et al (2001) Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol 11(5):370–374PubMedCrossRef

154.

Bryce NS, Clark ES, Leysath JL, Currie JD, Webb DJ, Weaver AM (2005) Cortactin promotes cell motility by enhancing lamellipodial persistence. Curr Biol 15(14):1276–1285PubMedCrossRef

155.

Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC (2006) Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66(6):3034–3043PubMedCrossRef

156.

Clark ES, Whigham AS, Yarbrough WG, Weaver AM (2007) Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 67(9):4227–4235PubMedCrossRef

157.

Weed SA, Parsons JT (2001) Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 20(44):6418–6434PubMedCrossRef

158.

Bowden ET, Onikoyi E, Slack R et al (2006) Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp Cell Res 312(8):1240–1253PubMedCrossRef

159.

Li Y, Tondravi M, Liu J et al (2001) Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 61(18):6906–6911PubMed

160.

Martinez-Quiles N, Ho HY, Kirschner MW, Ramesh N, Geha RS (2004) Erk/Src phosphorylation of cortactin acts as a switch on-switch off mechanism that controls its ability to activate N-WASP. Mol Cell Biol 24(12):5269–5280PubMedCrossRef

161.

Boeckers TM, Bockmann J, Kreutz MR, Gundelfinger ED (2002) ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem 81(5):903–910PubMedCrossRef

162.

Han W, Kim KH, Jo MJ et al (2006) Shank2 associates with and regulates Na+/H+ exchanger 3. J Biol Chem 281(3):1461–1469PubMedCrossRef

163.

Freier K, Sticht C, Hofele C et al (2006) Recurrent coamplification of cytoskeleton-associated genes EMS1 and SHANK2 with CCND1 in oral squamous cell carcinoma. Genes Chromosomes Cancer 45(2):118–125PubMedCrossRef

164.

Du Y, Weed SA, Xiong WC, Marshall TD, Parsons JT (1998) Identification of a novel cortactin SH3 domain-binding protein and its localization to growth cones of cultured neurons. Mol Cell Biol 18(10):5838–5851PubMed

165.

Lim S, Sala C, Yoon J et al (2001) Sharpin, a novel postsynaptic density protein that directly interacts with the shank family of proteins. Mol Cell Neurosci 17(2):385–397PubMedCrossRef

166.

Okamoto PM, Gamby C, Wells D, Fallon J, Vallee RB (2001) Dynamin isoform-specific interaction with the shank/ProSAP scaffolding proteins of the postsynaptic density and actin cytoskeleton. J Biol Chem 276(51):48458–48465PubMed

167.

Baldassarre M, Pompeo A, Beznoussenko G et al (2003) Dynamin participates in focal extracellular matrix degradation by invasive cells. Mol Biol Cell 14(3):1074–1084PubMedCrossRef

168.

Kumar R, Gururaj AE, Barnes CJ (2006) p21-activated kinases in cancer. Nat Rev Cancer 6(6):459–471PubMedCrossRef

169.

Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L (1994) A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367(6458):40–46PubMedCrossRef

170.

Papakonstanti EA, Stournaras C (2002) Association of PI-3 kinase with PAK1 leads to actin phosphorylation and cytoskeletal reorganization. Mol Biol Cell 13(8):2946–2962PubMedCrossRef

171.

Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J (1997) Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol 7(3):202–210PubMedCrossRef

172.

Sells MA, Boyd JT, Chernoff J (1999) p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol 145(4):837–849PubMedCrossRef

173.

Edwards DC, Sanders LC, Bokoch GM, Gill GN (1999) Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol 1(5):253–259PubMedCrossRef

174.

Yoshioka K, Foletta V, Bernard O, Itoh K (2003) A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 100(12):7247–7252PubMedCrossRef

175.

Vadlamudi RK, Li F, Barnes CJ, Bagheri-Yarmand R, Kumar R (2004) p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep 5(2):154–160PubMedCrossRef

176.

Vadlamudi RK, Li F, Adam L et al (2002) Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol 4(9):681–690PubMedCrossRef

177.

Webb BA, Zhou S, Eves R, Shen L, Jia L, Mak AS (2006) Phosphorylation of cortactin by p21-activated kinase. Arch Biochem Biophys 456(2):183–193PubMedCrossRef

178.

Yang Z, Bagheri-Yarmand R, Wang RA et al (2004) The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 10(2):658–667PubMedCrossRef

Titel: Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer
verfasst von: Laura C. Kelley
Sohrab Shahab
Scott A. Weed
Publikationsdatum: 01.06.2008
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 4/2008
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-008-9154-6

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis

Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma

Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis

Dissociated invasively growing cancer cells with NF-kappaB/p65 positivity after radiotherapy: a new marker for worse clinical outcome in rectal cancer? Preliminary data